Etude d’impact de la communication menée auprès des médecins prescripteurs d’Epitomax® et ses génériques en France

05/07/2018
01/04/2024
EU PAS number:
EUPAS24731
Study
Finalised
Study summary
No information provided.
Study identification

EU PAS number

EUPAS24731

Study ID

31433

Official title and acronym

Etude d’impact de la communication menée auprès des médecins prescripteurs d’Epitomax® et ses génériques en France

DARWIN EU® study

No

Study countries

France

Study description

No information provided.

Study status

Finalised
Research institutions and networks

Institutions

NA (database study]

Contact details

Cecile Deal

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Accord Healthcare, Arrow, Biogaran, EG Labo, Janssen, Sandoz, Mylan, Zydus
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable